Chinese researchers are preparing the details for the publication of another scientific milestone, the creation of a chimera with a human heart and a kidney developed from human stem cells in pig embryos. These studies aim to address the shortage of immunocompatible organ donors while shedding light on some of the most fundamental questions in developmental biology. Read More
Centessa Pharmaceuticals plc has obtained IND clearance from the FDA to initiate a phase I study of ORX-142 in healthy volunteers. ORX-142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative disorders. Read More
Researchers from Lifordi Immunotherapeutics Inc. have developed a novel antibody-drug conjugate (ADC) called LFD-200 that aims to selectively deliver a potent glucocorticoid (GC) payload directly to immune cells. This strategy may potentially offer a new way to treat autoimmune and inflammatory conditions while minimizing systemic toxicity. Read More
Alzheimer’s disease (AD) progression involves microglial activation, and restoring or maintaining microglia homeostasis is a therapeutic approach to fight against AD. Read More
Ascletis Pharma (China) Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), diabetes, obesity, metabolic syndrome and more. Read More
Diabetic kidney disease (DKD) is a chronic complication of type 1 and type 2 diabetes with albuminuria and progressive kidney failure; about 20%-40% of patients with diabetes will develop some type of kidney disease. Read More
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and damage of the joints. PET/CT imaging is a useful tool for early disease assessment and monitoring treatment efficacy. Read More
Systemic sclerosis (SSc) is a particularly severe form of fibrotic disease that affects multiple organs. SSc is the most deadly autoimmune rheumatic disease. Read More
Ariel Scientific Innovations Ltd. has identified dolastatin 10 analogues and its conjugates comprising another functional moiety and a linking moiety reported to be useful for the treatment of cancer. Read More
MBX Biosciences Inc. has submitted an IND application to the FDA for MBX-4291, a long-acting glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonist prodrug for the treatment of obesity. Read More
University of Sydney has synthesized translocator protein (TSPO; PBR) (A147T mutant) ligands reported to be useful for the diagnosis and treatment of neurological disorders. Read More
Biogen Inc. has disclosed huntingtin (HTT; HD) (mutant) splicing modulators reported to be useful for the treatment of Huntington’s disease and spinal muscular atrophy (SMA). Read More
Ibio Inc. has nominated IBIO-610 as a development candidate for its first-in-class Activin E antibody program and initiated a nonhuman primate (NHP) study. Read More
